The UPC has now been running for three years. With first instance proceedings typically taking around one year and appeals taking a similar period, now is perhaps the first opportunity to, cautiously, look at a sufficiently mature body of Court of Appeal decisions and seek to identify patterns.
Appeals in the UPC, as for most courts, are to a material extent self-selecting. Parties are less likely to appeal clear cut decisions, while cases with a realistic prospect of success are more likely to proceed. Even though the UPC requires no permission to appeal final decisions, the fact that appeals at the UPC do not automatically have a suspensory effect (as in the EPO, for instance) or offer material procedural advantage, would reduce incentives for parties to file more ‘ambitious’ appeals. Moreover, additional disagreement between first instance and appeal is also unsurprising at this stage, while the UPC remains a relatively young court and its case law is still settling. Against that backdrop, an overturn rate of just over half for both substantive appeals and appeals on the grant of a preliminary injunction (56% or five out of nine for substantive appeals; 56% or 9 out of 16 for appeals on preliminary injunctions) feels broadly in line with what one would expect.
UPC Court of Appeal: overturn rate by appeal type
Substantive appeals
Preliminary injunction appeals
Overturn rate
56%
56%
Decisions overturned
5 of 9
9 of 16
Within both categories of appeals, decisions are being overturned for a range of reasons. Some notable developments are as follows:
On provisional injunction appeals, the Court of Appeal has generally conducted a detailed substantive review of the questions of novelty and infringement, mirroring what seems to have become common at first instance as well. It is not at all unusual for judgments to include 20-30 pages (or more) on the assessment of validity and infringement. However, the consideration of urgency has also been a source of reversal on appeal. Given that suspensive effect is not generally granted for appeals of provisional injunctions, the value of an appeal over-turning a provisional injunction seems rather limited since in the meantime there is time for the first instance substantive decision to be either already available or expected soon.
For substantive appeals, again there is a range of reasons why the appeal outcome varied from first instance. Sometimes (as also in the first successful PI appeal of Nanostring v 10x Genomics) a difference in claim construction leads to a difference in conclusion on either validity or infringement.
The Kodak v Fujifilm appeal was particularly interesting as much of the substantive analysis on appeal differed little from that at first instance, but the Court of Appeal recognised a prior user right in respect of Germany that the first instance had not considered substantiated, while in respect of the UK the defendants were considered not the parties responsible for the UK acts.
On the patentee-friendliness of the Court of Appeal, it is interesting that despite over half the appeals succeeding, the overall rate of success rate of patentees is unchanged following appeals. In five of the nine first instance decisions that were appealed, there had been a finding that a patent was valid and infringed. Following appeal, there was found to be a valid and infringed patent in five of the nine cases. This would suggest that overall the Court of Appeal is no more pro- or anti-patentee than the first instance courts.
UPC Court of Appeal: patentee success rate before and after appeal
First instance decisions
On appeal
Valid and infringed
5 of 9
5 of 9
UPC Court of Appeal: preliminary injunction appeals
OverturnedUpheld
Parties
Date
Reference
First Instance – injunction granted
Appeal – decision on injunction
NanoString v 10x Genomics
26 February 2024
UPC_CoA_335/2023
Preliminary injunction granted
Overturned – patent likely invalid for obviousness
SES-imagotag SA v. Hanshow Technology
13 May 2024
UPC_CoA_1/2024
Preliminary injunction refused
Upheld
Mammut Sports Group v. Ortovox Sportartikel
25 September 2024
UPC_CoA_182/2024
Preliminary injunction granted
Upheld
SharkNinja v. Dyson
03 December 2024
UPC_CoA_297/2024
Preliminary injunction granted
Overturned – patent likely not infringed
Alexion Pharmaceuticals, Inc. v. Samsung Bioepis & Amgen
20 December 2024
UPC_CoA_402/2024
UPC_CoA_405/2024
Preliminary injunction refused – patent likely to be found invalid in parallel EPO proceedings
Upheld
Abbott Diabetes Care Inc. v. Sibio Technology Limited
14 February 2025
UPC_CoA_382/2024
Preliminary injunction refused – patent held likely invalid for added matter
Overturned – patent found likely to be valid
Sumi Agro Europe v. Syngenta
04 March 2025
UPC_CoA_523/2024
Preliminary injunction granted
Upheld
Insulet Corporation v. EOFLOW
01 May 2025
UPC_CoA_768/2024
Preliminary injunction refused – patent likely not novel
Overturned – CoA found patent to be likely valid and infringed
Boehringer Ingelheim v Zentiva
13 August 2025
UPC_CoA_446/2025
UPC_CoA_520/2025
Preliminary injunction refused – found to be lack of imminent infringement
Overturned – Preliminary injunction granted on urgency grounds
OTEC v. Steros
07 November 2025
UPC_CoA_579/2025
Preliminary injunction granted
Overturned – patent likely not infringed
Barco v. Yealink
28 November 2025
UPC_CoA_317/2025
Preliminary injunction refused – lack of urgency
Upheld
ONWARD Medical v. Niche Biomedical, Inc.
27 March 2026
UPC-COA-898/2025
Preliminary injunction refused
Upheld
Sinocare v. Abbott
30 March 2026
UPC-COA-899/2025
Preliminary injunction granted
Upheld
Abbott v. Sinocare
17 April 2026
UPC-COA-901/2025
Preliminary injunction refused – patent likely not infringed
Overturned – CoA found patent likely valid and infringed
Merz Pharmaceuticals v. Viatris Santé
27 April 2026
UPC-COA-917/2025
Preliminary injunction refused – lack of urgency; proportionality of injunction
Overturned on urgency and proportionality grounds
Occlutech v Lepu Medical
18 June 2026
UPC_CoA_907/2025
Preliminary injunction refused – patent likely not infringed
Overturned – patent likely infringed
UPC Court of Appeal: substantive appeals
OverturnedUpheldOther outcome
Parties
Date
Reference
First Instance
Appeal – Validity
Appeal – Infringement
Expert e-Commerce GmbH v. Seoul Viosys
2 October 2025
UPC_CoA_764/2024
Patent found valid and infringed
Overturned – patent invalid for added matter
Not considered
Philips v. Belkin
3 October 2025
UPC_CoA_534/2024
UPC_CoA_19/2025
UPC_CoA_683/2024
Patent found valid and infringed
Upheld.
Upheld
Seoul Viosys v. expert e-Commerce
6 November 2025
UPC_CoA_762/2024
UPC_CoA_773/2024
Patent held invalid for added matter
Upheld
Not considered
Amgen, Inc. v. Sanofi & Regeneron
25 November 2025
UPC_CoA_528/2024
UPC_CoA_529/2024
Patent found invalid for lack of inventive step
Overturned – patent found to be valid
Stayed at first instance
Meril v Edwards Lifesciences
25 November 2025
UPC_CoA_530/2024 UPC_CoA_464/2024
Patent found valid and infringed
Upheld
Upheld
VMR Products LLC v. NJOY Netherlands B.V.
5 January 2026
UPC_CoA_71/2025
Patent found invalid for lack of inventive step
Upheld
Not considered
Rematec GmbH & Co KG v Europe Forestry B.V.
18 February 2026
UPC_CoA_302/2025
UPC_CoA_305/2025
Patent found invalid for lack of novelty
Overturned
N/A (no first instance findings, however the CoA held the patent was infringed and granted injunction)
Hefei Xinhu v. Grundfos
27 May 2026
UPC_CoA_622/2025
Patent found valid and infringed
Overturned – patent partly revoked
N/A (relevant claims of patent revoked)
Kodak v Fujifilm
2 June 2026
UPC-CoA-312/2025
UPC-CoA-333/2025
UPC-CoA-880/2025
UPC-CoA-882/2025
Patent found valid and infringed
Upheld
Overturned
The Latest Thought Leadership pieces in the Content Hub
Oops! Something went wrong while submitting the form.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.